GH Research Analyst Ratings
Buy Rating Affirmed for GH Research Amid Promising Trials and Regulatory Milestones
GH Research Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Veru (VERU) and GH Research (GHRS)
GH Research Analyst Ratings
Buy Rating for GH Research: Promising Clinical Trials and Strategic Intellectual Property Advances
GH Research Analyst Ratings
Buy Rating Justified by GH Research's Promising Clinical Trials and Strong Financial Health
Optimistic Outlook for GH Research With Progressing Phase 2 Trials and Strong IP Portfolio Reinforcing Buy Rating
GH Research Analyst Ratings
Stifel Maintains Buy on GH Research, Lowers Price Target to $18
GH Research Analyst Ratings
GH Research Analyst Ratings
Analysts Offer Insights on Technology Companies: Inuvo (INUV) and GH Research (GHRS)
GH Research Earns 'Buy' Rating: Promising Progress, Proactive Approach, and Solid Financial Standing
Positive Outlook for GH Research Despite FDA's Clinical Hold: An Analysis of GH001's Trials and Prospects
GH Research: Temporary FDA Setback and Promising European Trials Bolster Buy Rating
H.C. Wainwright Sticks to Their Buy Rating for GH Research (GHRS)
GH Research (GHRS) Gets a Buy From JMP Securities
H.C. Wainwright Keeps Their Buy Rating on GH Research (GHRS)
No Data